170 related articles for article (PubMed ID: 36493943)
1. Updated systematic assessment of human, animal and mechanistic evidence demonstrates lack of human carcinogenicity with consumption of aspartame.
Borghoff SJ; Cohen SS; Jiang X; Lea IA; Klaren WD; Chappell GA; Britt JK; Rivera BN; Choski NY; Wikoff DS
Food Chem Toxicol; 2023 Feb; 172():113549. PubMed ID: 36493943
[TBL] [Abstract][Full Text] [Related]
2. Lack of potential carcinogenicity for aspartame - Systematic evaluation and integration of mechanistic data into the totality of the evidence.
Wikoff DS; Chappell GA; Fitch S; Doepker CL; Borghoff SJ
Food Chem Toxicol; 2020 Jan; 135():110866. PubMed ID: 31614175
[TBL] [Abstract][Full Text] [Related]
3. Histological analyses of the Ishii (1981) rat carcinogenicity study of aspartame and comparison with the Ramazzini Institute studies.
Shibui Y; Fujitani S; Iwata H; Lynch B; Roberts A
Regul Toxicol Pharmacol; 2019 Mar; 102():23-29. PubMed ID: 30572082
[TBL] [Abstract][Full Text] [Related]
4. Pathologists' perspective on the study design, analysis, and interpretation of proliferative lesions in lifetime and prenatal rodent carcinogenicity bioassays of aspartame.
Elmore SA; Rehg JE; Schoeb TR; Everitt JI; Bolon B
Food Chem Toxicol; 2023 Jan; 171():113504. PubMed ID: 36414169
[TBL] [Abstract][Full Text] [Related]
5. Aspartame, a bittersweet pill.
Paolini M; Vivarelli F; Sapone A; Canistro D
Carcinogenesis; 2017 Dec; 38(12):1249-1250. PubMed ID: 26912665
[TBL] [Abstract][Full Text] [Related]
6. NTP report on the toxicology studies of aspartame (CAS No. 22839-47-0) in genetically modified (FVB Tg.AC hemizygous) and B6.129-Cdkn2atm1Rdp (N2) deficient mice and carcinogenicity studies of aspartame in genetically modified [B6.129-Trp53tm1Brd (N5) haploinsufficient] mice (feed studies).
National Toxicology Program
Natl Toxicol Program Genet Modif Model Rep; 2005 Oct; (1):1-222. PubMed ID: 18685711
[TBL] [Abstract][Full Text] [Related]
7. The carcinogenic effects of aspartame: The urgent need for regulatory re-evaluation.
Soffritti M; Padovani M; Tibaldi E; Falcioni L; Manservisi F; Belpoggi F
Am J Ind Med; 2014 Apr; 57(4):383-97. PubMed ID: 24436139
[TBL] [Abstract][Full Text] [Related]
8. Lack of potential carcinogenicity for sucralose - Systematic evaluation and integration of mechanistic data into the totality of the evidence.
Chappell GA; Borghoff SJ; Pham LL; Doepker CL; Wikoff DS
Food Chem Toxicol; 2020 Jan; 135():110898. PubMed ID: 31654706
[TBL] [Abstract][Full Text] [Related]
9. Aspartame carcinogenic potential revealed through network toxicology and molecular docking insights.
Chen D; Hou X
Sci Rep; 2024 May; 14(1):11492. PubMed ID: 38769413
[TBL] [Abstract][Full Text] [Related]
10. Life-span exposure to low doses of aspartame beginning during prenatal life increases cancer effects in rats.
Soffritti M; Belpoggi F; Tibaldi E; Esposti DD; Lauriola M
Environ Health Perspect; 2007 Sep; 115(9):1293-7. PubMed ID: 17805418
[TBL] [Abstract][Full Text] [Related]
11. Aspartame and cancer - new evidence for causation.
Landrigan PJ; Straif K
Environ Health; 2021 Apr; 20(1):42. PubMed ID: 33845854
[TBL] [Abstract][Full Text] [Related]
12. Pathologists' perspective on the study design, analysis, and interpretation of proliferative lesions in a lifetime rodent carcinogenicity bioassay of sucralose.
Elmore SA; Rehg JE; Schoeb TR; Everitt JI; Bolon B
Food Chem Toxicol; 2024 Jun; 188():114524. PubMed ID: 38428799
[TBL] [Abstract][Full Text] [Related]
13. Systematic review and evaluation of aspartame carcinogenicity bioassays using quality criteria.
Haighton L; Roberts A; Walters B; Lynch B
Regul Toxicol Pharmacol; 2019 Apr; 103():332-344. PubMed ID: 29339245
[TBL] [Abstract][Full Text] [Related]
14. Consequences of exposure to carcinogens beginning during developmental life.
Soffritti M; Belpoggi F; Esposti DD; Falcioni L; Bua L
Basic Clin Pharmacol Toxicol; 2008 Feb; 102(2):118-24. PubMed ID: 18226064
[TBL] [Abstract][Full Text] [Related]
15. Aspartame: a safety evaluation based on current use levels, regulations, and toxicological and epidemiological studies.
Magnuson BA; Burdock GA; Doull J; Kroes RM; Marsh GM; Pariza MW; Spencer PS; Waddell WJ; Walker R; Williams GM
Crit Rev Toxicol; 2007; 37(8):629-727. PubMed ID: 17828671
[TBL] [Abstract][Full Text] [Related]
16. Results of long-term carcinogenicity bioassay on Sprague-Dawley rats exposed to aspartame administered in feed.
Belpoggi F; Soffritti M; Padovani M; Degli Esposti D; Lauriola M; Minardi F
Ann N Y Acad Sci; 2006 Sep; 1076():559-77. PubMed ID: 17119233
[TBL] [Abstract][Full Text] [Related]
17. Aspartame and Risk of Cancer: A Meta-analytic Review.
Mallikarjun S; Sieburth RM
Arch Environ Occup Health; 2015; 70(3):133-41. PubMed ID: 24965331
[TBL] [Abstract][Full Text] [Related]
18. Non-sugar sweeteners and cancer: Toxicological and epidemiological evidence.
Pavanello S; Moretto A; La Vecchia C; Alicandro G
Regul Toxicol Pharmacol; 2023 Mar; 139():105369. PubMed ID: 36870410
[TBL] [Abstract][Full Text] [Related]
19. Overall lack of genotoxic activity among five common low- and no-calorie sweeteners: A contemporary review of the collective evidence.
Lea IA; Chappell GA; Wikoff DS
Mutat Res Genet Toxicol Environ Mutagen; 2021; 868-869():503389. PubMed ID: 34454695
[TBL] [Abstract][Full Text] [Related]
20. Lack of potential carcinogenicity for acesulfame potassium - Systematic evaluation and integration of mechanistic data into the totality of the evidence.
Chappell GA; Wikoff DS; Doepker CL; Borghoff SJ
Food Chem Toxicol; 2020 Jul; 141():111375. PubMed ID: 32360221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
